Have you forgotten Dadri? Bajrang Dal asks beef eaters in Mangaluru

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Mangalore, May 2: More than 500 families received ration kits in a distribution drive conducted by St Agnes College in outskirts of Mangaluru on Wednesday.

Since the lockdown was announced, the management, staff and alumni of St Agnes College are playing an active role in ensuring no one is deprived of food and essentials during these challenging pandemic times.

The College as part of its Agnes towards Community (ATC) programme had adopted villages such as Munnur, Harekala, Amlamogaru, Someshwara and Pavur. Various development drives are conducted in these villages by the staff and students. However, due to the COVID-19 lockdown, the activities undertaken in these villages were kept on hold.

The College recently received information from its network that several families in these villages are struggling for food and essentials.

The College management in association with its alumni and well-wishers took-up the initiative to distribute ration kits consisting of rice, dal, spices, tea powder, hygiene products and other essentials to 500 needy families belonging to these villages.

The drive was held in presence of Zilla Panchayat member Dhanalakshmi Gatty and other Gram Panchayat members.

"We were able to provide food to 600 and more families in different villages and to the stranded migrant workers in the city during this time of crisis because of the generous contributions of our staff, alumni and well wishes" says Sr Dr. M. Jeswina A.C.

The College management expresses its gratitude to all donors, especially the staff, alumni and those associated with the college.

Bengaluru, Mar 11: The Insurance Regulatory Authority of India has asked insurers to settle all claims related to coronavirus expeditiously under existing health policies that provide for treatment of hospitalisation expenses.

It has also asked insurers to design products covering the cost of treatment of coronavirus that has fast spread across the world and also resulted in increasing number of infections in India. There has been over 3,000 deaths globally and 58 cases tested positive in India.

In order to provide need-based health insurance coverage, insurers are intro ducing products for various specific diseases, including vector borne diseases. "For the purpose of meeting health insurance requirements of various sections, insurers are advised to design products covering the costs of treatment for coronavirus," the IRDAI said in a circular.

The regulator said that under existing health insurance policies where hospitalisation is covered, not only the cases related to coronvirus disease (COVID-19) shall be expeditiously handled, but all the costs of admissible medic al expenses during the course of treatment, including the treatment during quarantine period, should be settled in accordance to the applicable terms and conditions of policy contract and the extant regulatory framework.

This would bring much needed relief to policy holders some of whom were facing difficulty in getting coverage for treatment takers to coronavirus. In the absence of clear information, a few hospitals were reportedly denying for forward such claims of policy holders to the insurers.

IRDAI has now said that all the claims reported under COVID-19 shall be thoro ughly reviewed by review committee before repudiating the claims. This would prevent blanket rejection of such claims.

But to get full claim for treatment of coronavirus, industry experts said, a person should be hospitalised at least for 24 hours. Most insurers do not c over outpatient treatment.